Meeting
2019 ASCO Annual Meeting
Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.
Authors
Jing Wu
NCI, Bethesda, MD
Jing Wu , Ying Yuan , Christine Cordova , Orwa Aboud , Marta Penas-Prado , Brett James Theeler , Christine Bryla , Yu-Ting Su , Ewa Grajkowska , Ann McCoy , Lisa Boris , Christine Siegel , Ramya Antony , Nancy Garren , Tracy Lawhon , Terri Armstrong , Mark R. Gilbert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02942264
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2031)
DOI
10.1200/JCO.2019.37.15_suppl.2031
Abstract #
2031
Poster Bd #
220
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas
Poster
2018 ASCO Annual Meeting
Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.
First Author: Oana C. Danciu
Poster
2017 ASCO Annual Meeting
Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma multiforme.
First Author: Danielle A. Shafer
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih